Hypertension

Also in TTHealthWatch: CVD death and obesity

Selective aldosterone synthase inhibitor proceeds to phase III study after Target-HTN's success

Also in TTHealthWatch: culprit vessel or complete revascularization?

But researcher says there's no need to switch most users to other antihypertensive drugs

Also in TTHealthWatch: effect of frailty on intensive blood pressure control

Once resurrected, is radiofrequency renal denervation heading back to limbo?

Device-based treatment passes hurdle despite concerns about effectiveness

Device-based hypertension treatments have only modest BP reductions

Risk stratification with or without obstructive coronary disease

Also in TTHealthWatch: Interfering RNA for hypertension and "weekend warrior" exercise

Injections stop liver-specific synthesis of angiotensinogen

BP trajectories improve on prediction using standard risk factors alone

Meta-analysis shows highest glaucoma risk with CCB monotherapy, reduced IOP with beta-blockers

Novel risk factor did not hinge on preeclampsia